| Ms Paula M Rozman, LPN | |
|
87-2872 Mamalahoa Hwy, Captain Cook, HI 96704-8758 | |
| (808) 339-2305 | |
| Not Available |
| Full Name | Ms Paula M Rozman |
|---|---|
| Gender | Female |
| Speciality | Licensed Practical Nurse |
| Location | 87-2872 Mamalahoa Hwy, Captain Cook, Hawaii |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184918070 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164W00000X | Licensed Practical Nurse | 31885-31 (Wisconsin) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Paula M Rozman, LPN Po Box 1842, Kailua Kona, HI 96745-1842 Ph: (808) 339-2305 | Ms Paula M Rozman, LPN 87-2872 Mamalahoa Hwy, Captain Cook, HI 96704-8758 Ph: (808) 339-2305 |
News Archive
The holiday season is officially in full gear and with it comes the tempting Thanksgiving-to-New-Year's food fest. While research shows that the average person really only gains about a pound over the course of the holidays, it can still have a big cumulative effect on waistlines. That's because the extra weight usually doesn't come off the following year.
CVRx, Inc. announced today the four-year Rheos clinical results from the European study evaluating the Rheos System at the European Society of Hypertension 20th Meeting. The system is the first device designed to treat hypertension (high blood pressure), a leading cause of heart and kidney disease, stroke and death. This device is a future treatment option for the millions of people who cannot control their blood pressure with medications.
Spatial Integrated Systems, Inc., a leader in the development and integration of solutions incorporating next generation digital 3D data capture and processing technologies, announced today that it has been awarded U.S. patent 7,986,321 for a system and method for generating structured light for three-dimensional image rendering.
The Lankenau Institute for Medical Research (LIMR) announced that in collaboration with the Massachusetts Institute of Technology (MIT) they have performed preclinical proof-of- principle studies showing how nanotechnology can be used to enhance gene therapy for cancer.
In an examination of the appropriateness of the widespread use of percutaneous coronary interventions (PCIs), researchers found that of more than 500,000 PCIs included in the study, nearly all for acute indications were classified as appropriate, whereas only about half of PCIs performed for nonacute indications could be classified as appropriate, according to a study in the July 6 issue of JAMA.
› Verified 1 days ago